| Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia JE Megías-Vericat, A Solana-Altabella, O Ballesta-López, ... Annals of Hematology 99 (9), 1989-2007, 2020 | 30 | 2020 |
| Computer vision-based analytical chemistry applied to determining iron in commercial pharmaceutical formulations A Solana-Altabella, MH Sánchez-Iranzo, JI Bueso-Bordils, ... Talanta 188, 349-355, 2018 | 18 | 2018 |
| Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia JE Megias-Vericat, D Martinez-Cuadron, MJ Herrero, R Rodriguez-Veiga, ... Leukemia & Lymphoma 62 (3), 659-668, 2021 | 12 | 2021 |
| Pre and post intervention study of antiblastic drugs contamination surface levels at a Pharmacy Department Compounding Area using a closed system drug transfer device and a … S Valero, E López-Briz, N Vila, A Solana, M Melero, JL Poveda Regulatory Toxicology and Pharmacology 95, 1-7, 2018 | 10 | 2018 |
| Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia A Solana-Altabella, O Ballesta-Lopez, JE Megias-Vericat, ... Expert Opinion on Emerging Drugs 27 (1), 1-18, 2022 | 6 | 2022 |
| Developing a telepharmacy programme with home medication dispensing and informed delivery in a tertiary hospital: description of the model and analysis of the results M Gil-Candel, A Solana-Altabella, E Vicente-Escrig, A Puplá-Bartoll, ... European Journal of Hospital Pharmacy 30 (2), 107-112, 2023 | 5 | 2023 |
| Systematic review of pharmacogenetics of ABC and SLC transporter genes in acute myeloid leukemia JE Megías-Vericat, D Martínez-Cuadrón, A Solana-Altabella, JL Poveda, ... Pharmaceutics 14 (4), 878, 2022 | 5 | 2022 |
| Intravitreal melphalan therapy for vitreous seeds in retinoblastoma: Implementation and outcomes of a new chemotherapy protocol A Solana-Altabella, S Valero, J Balaguer, P Escobar-Cava, H Barranco, ... Journal of Oncology Pharmacy Practice 26 (8), 1829-1835, 2020 | 5 | 2020 |
| Precision medicine in acute myeloid leukemia: where are we now and what does the future hold? JE Megías-Vericat, D Martínez-Cuadrón, A Solana-Altabella, ... Expert Review of Hematology 13 (10), 1057-1065, 2020 | 5 | 2020 |
| Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia JE Megías-Vericat, D Martínez-Cuadrón, MJ Herrero, R Rodríguez-Veiga, ... Pharmacogenetics and Genomics 31 (6), 133-139, 2021 | 4 | 2021 |
| Influence of pharmacokinetic/pharmacodynamic ratio on vancomycin treatment response in paediatric patients with Staphylococcus aureus bacteremia J Ruiz, A Garcia-Robles, MR Marques, A Solana, JL Poveda Minerva Pediatr, 2018 | 4 | 2018 |
| Haemodialysis significantly reduces serum levetiracetam levels inducing epileptic seizures: Case report. J Ruíz‐Ramos, A Solana Altabella, MR Marqués‐Miñana, C Vicent, ... Journal of Clinical Pharmacy & Therapeutics 42 (6), 2017 | 3 | 2017 |
| Healthcare Resource Utilization among Patients between 60–75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective … A Solana-Altabella, JE Megías-Vericat, O Ballesta-López, B Boluda, ... Cancers 14 (8), 1921, 2022 | 2 | 2022 |
| Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation O Ballesta-López, A Solana-Altabella, JE Megías-Vericat, ... Future Oncology 17 (2), 215-227, 2020 | 2 | 2020 |
| Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the … D Martínez-Cuadrón, JE Megías-Vericat, C Gil, T Bernal, M Tormo, ... Haematologica 109 (1), 115, 2024 | 1 | 2024 |
| Incidence and risk factors for development of cardiac toxicity in adult patients with newly diagnosed acute myeloid leukemia B Boluda, A Solana-Altabella, I Cano, D Martínez-Cuadrón, E Acuña-Cruz, ... Cancers 15 (8), 2267, 2023 | 1 | 2023 |
| Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients B Boluda, D Martínez-Cuadrón, L Algarra, I Cano, MJ Sayas, ... Leukemia & Lymphoma 62 (11), 2727-2736, 2021 | 1 | 2021 |
| Extracorporeal photopheresis vs standard therapies for steroid‐refractory chronic graft‐vs‐host disease: Pharmacoeconomic assessment of hospital resource use in Spain B Boluda, A Solana‐Altabella, I Cano, E Acuña‐Cruz, R Rodríguez‐Veiga, ... Journal of Clinical Apheresis 36 (4), 612-620, 2021 | 1 | 2021 |
| Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain A Solana‐Altabella, B Boluda, R Rodríguez‐Veiga, I Cano, E Acuña‐Cruz, ... European Journal of Haematology 106 (5), 724-733, 2021 | 1 | 2021 |
| CP-078 Prostaglandin E1 injection after arterial compromise related to hyaluronic acid filler H Ribes, JE Megías, JM Ricart, A Solana, JL Poveda European Journal of Hospital Pharmacy 24 (Suppl 1), A34-A35, 2017 | 1 | 2017 |
Miguel SanzHospital Universitario La FeVerified email at uv.es
